SLC5A2 and diabetes mellitus: In particular, in the REFORM study (Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes), a randomized, double-blind, single-center study, in 56 patients with DM and HF with LVEF < 45%, dapagliflozin administration for 12 months had no effect on LV remodeling (i.e., left atrial volume index/LAVI, left ventricular end-systolic volume index/LVESVI, left ventricular end-diastolic volume index/LVEDVI and left ventricular mass index/LVMI) [14].